Flavonoids inhibit angiogenic cytokine production by human glioma cells
Article first published online: 17 DEC 2010
Copyright © 2010 John Wiley & Sons, Ltd.
Volume 25, Issue 6, pages 916–921, June 2011
How to Cite
Freitas, S., Costa, S., Azevedo, C., Carvalho, G., Freire, S., Barbosa, P., Velozo, E., Schaer, R., Tardy, M., Meyer, R. and Nascimento, I. (2011), Flavonoids inhibit angiogenic cytokine production by human glioma cells. Phytother. Res., 25: 916–921. doi: 10.1002/ptr.3338
- Issue published online: 11 MAR 2011
- Article first published online: 17 DEC 2010
- Manuscript Accepted: 30 SEP 2010
- Manuscript Revised: 28 JAN 2009
- Manuscript Received: 17 NOV 2008
- angiogenic factor inhibitors;
VEGF and TGF-β1 are cytokines that stimulate tissue invasion and angiogenesis. These factors are considered as molecular targets for the therapy of glioblastoma. Bevacizumab, a recombinant humanized monoclonal antibody developed against VEGF, inhibits endothelial cell proliferation and vessel formation. Flavonoids obtained from Dimorphandra mollis and Croton betulaster have been described as proliferation inhibitors of a human glioblastoma derived cell line. VEGF and TGF-β1 levels were dosed by ELISA in a GL-15 cell line treated with bevacizumab and also with the flavonoids rutin, 5-hydroxy-7,4′-dimethoxyflavone, casticin, apigenin and penduletin. Rutin reduced the VEGF and TGF-β1 levels after 24 h but not after 72 h. The other flavonoids significantly reduced TGF-β1 production. Bevacizumab reduced only the VEGF levels in the supernatant from GL-15 cultures. These results suggest that the flavonoids studied, and commonly used in popular medicine, present an interesting subject of study due to their potential effect as angiogenic factor inhibitors. Copyright © 2010 John Wiley & Sons, Ltd.